The Company Behind Ozempic Thinks AI Could Unlock Entirely New Medicines
Denmark’s Novo Nordisk announced on September 16, 2026 a partnership with Anthropic: Claude and Claude Science models will be used in research and software development. This is the company’s second major AI deal in five months — in April 2026 it signed an agreement with OpenAI. Deal amounts were not disclosed.
- Claude Science will be used for literature synthesis and hypothesis evaluation
- OpenAI integration is due to be completed by the end of 2026
- Goal is to speed up research in the GLP-1 drug market
- Amount of both deals not disclosed
Read next
AI